LPCN
Lipocine Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.
Market Cap: 19 Million
Primary Exchange: NASDAQ
Website: https://www.lipocine.com/
Shares Outstanding: 5.32 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.4717280388431552
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2166 trading days
From: 2015-09-08 To: 2023-05-11
Lowest Point:
Antares Pharma: What The Market Is Missing
via: SeekingAlpha at 2019-06-11 01:18:27:000
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...
Antares Pharma: What The Market Is Missing
via: SeekingAlpha at 2019-06-11 01:18:27:000
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...
Antares Pharma: What The Market Is Missing
via: SeekingAlpha at 2019-06-11 01:18:27:000
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|